Evoke Pharma Inc (EVOK)
4.41
-0.09
(-2.00%)
USD |
NASDAQ |
Nov 22, 14:38
Evoke Pharma Enterprise Value: 0.348M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
November 21, 2024 | 0.348M |
November 20, 2024 | 0.4371M |
November 19, 2024 | 0.6452M |
November 18, 2024 | 0.1548M |
November 15, 2024 | 0.4668M |
November 14, 2024 | 0.1485M |
November 13, 2024 | -0.0087M |
November 12, 2024 | 1.091M |
November 11, 2024 | 1.656M |
November 08, 2024 | 2.057M |
November 07, 2024 | 2.061M |
November 06, 2024 | 2.339M |
November 05, 2024 | -1.158M |
November 04, 2024 | -1.221M |
November 01, 2024 | -1.149M |
October 31, 2024 | -1.104M |
October 30, 2024 | -0.5676M |
October 29, 2024 | -0.7018M |
October 28, 2024 | -0.0038M |
October 25, 2024 | -1.597M |
October 24, 2024 | -1.749M |
October 23, 2024 | -1.749M |
October 22, 2024 | -1.507M |
October 21, 2024 | -1.436M |
October 18, 2024 | -1.409M |
Date | Value |
---|---|
October 17, 2024 | -1.564M |
October 16, 2024 | -1.740M |
October 15, 2024 | -1.767M |
October 14, 2024 | -1.785M |
October 11, 2024 | -1.695M |
October 10, 2024 | -1.579M |
October 09, 2024 | -1.713M |
October 08, 2024 | -1.355M |
October 07, 2024 | -1.525M |
October 04, 2024 | -1.641M |
October 03, 2024 | -1.686M |
October 02, 2024 | -1.910M |
October 01, 2024 | -1.981M |
September 30, 2024 | -2.080M |
September 27, 2024 | -0.237M |
September 26, 2024 | -0.0158M |
September 25, 2024 | -0.2452M |
September 24, 2024 | -0.0813M |
September 23, 2024 | 0.1317M |
September 20, 2024 | -0.4828M |
September 19, 2024 | -0.5401M |
September 18, 2024 | -0.704M |
September 17, 2024 | -0.6057M |
September 16, 2024 | -0.7196M |
September 13, 2024 | -0.6467M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.545M
Minimum
Nov 22 2022
142.35M
Maximum
Aug 14 2020
24.72M
Average
8.964M
Median
Jan 25 2023
Enterprise Value Benchmarks
Repligen Corp | 7.680B |
Eli Lilly and Co | 739.59B |
MEI Pharma Inc | -8.182M |
Revance Therapeutics Inc | 649.94M |
NovaBay Pharmaceuticals Inc | 2.798M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -1.312M |
Revenue (Quarterly) | 2.654M |
Total Expenses (Quarterly) | 3.940M |
EPS Diluted (Quarterly) | -0.94 |
Gross Profit Margin (Quarterly) | 96.08% |
Profit Margin (Quarterly) | -49.45% |
Earnings Yield | -250.1% |
Normalized Earnings Yield | -250.11 |